Literature DB >> 18057533

Expression of MAGE-A12 in oral squamous cell carcinoma.

Nur Mollaoglu1, Eleftherios Vairaktaris, Emeka Nkenke, Friedrich W Neukam, Jutta Ries.   

Abstract

Melanoma associated-A antigens (MAGE-A) are silent in normal tissues except testis. However, they are activated ina variety of different tumors. Thus, their expression is highly specific to cancer cells. Reverse transcription-nested polymerase chain reaction (RT-nPCR) is a highly sensitive technique that has been used successfully for the detection of MAGE genes in tissue samples. The aim of the study is to analyze the expression rate of MAGE-A12 in oral squamous cell carcinoma (OSCC) using a high sensitive RT-nPCR. Total of 57 tissue samples obtained from patients with OSCC and 20 normal oral mucosal (NOM) probes of otherwise healthy volunteers were included to this study. No expression of MAGE-A12 was observed in the non-neoplasticNOM tissues. MAGE-A12 was expressed in 49.1% of the investigated tumor samples. The correlation between malignant lesion and MAGE-A12 detection was significant (p<0.001). It is concluded that results of this study may indicate MAGE-A12 asa useful additional diagnostic marker especially for the early detection of OSCC distinguishing neoplastic transformation and detection of occult and/or rare disseminated cancer cells. In addition, MAGE-A12 expression in OSCC may also determine anew immunotherapeutic target and might be warranted to develop vaccine for OSCC

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18057533      PMCID: PMC3850551          DOI: 10.1155/2008/359840

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  8 in total

1.  Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

Authors:  Stefan Hartmann; Roman C Brands; Nora Küchler; Andreas Fuchs; Christian Linz; Alexander C Kübler; Urs D A Müller-Richter
Journal:  Oncol Lett       Date:  2015-06-09       Impact factor: 2.967

2.  Altered epigenetic regulation of homeobox genes in human oral squamous cell carcinoma cells.

Authors:  Katarzyna M Marcinkiewicz; Lorraine J Gudas
Journal:  Exp Cell Res       Date:  2013-09-25       Impact factor: 3.905

3.  Differential gene expression and network analysis in head and neck squamous cell carcinoma.

Authors:  Insan Habib; Farah Anjum; Taj Mohammad; Md Nayab Sulaimani; Alaa Shafie; Mazen Almehmadi; Dharmendra Kumar Yadav; Sukhwinder Singh Sohal; Md Imtaiyaz Hassan
Journal:  Mol Cell Biochem       Date:  2022-02-10       Impact factor: 3.396

4.  Discovery and validation of DNA hypomethylation biomarkers for liver cancer using HRM-specific probes.

Authors:  Barbara Stefanska; Aurelie Bouzelmat; Jian Huang; Matthew Suderman; Michael Hallett; Ze-Guang Han; Mamun Al-Mahtab; Sheikh Mohammad Fazle Akbar; Wasif Ali Khan; Rubhana Raqib; Moshe Szyf
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

5.  Integrative DNA methylation and gene expression analysis to assess the universality of the CpG island methylator phenotype.

Authors:  Matahi Moarii; Fabien Reyal; Jean-Philippe Vert
Journal:  Hum Genomics       Date:  2015-10-13       Impact factor: 4.639

6.  Identification of genes and critical control proteins associated with inflammatory breast cancer using network controllability.

Authors:  Ryouji Wakai; Masayuki Ishitsuka; Toshihiko Kishimoto; Tomoshiro Ochiai; Jose C Nacher
Journal:  PLoS One       Date:  2017-11-06       Impact factor: 3.240

7.  Melanoma antigen A12 regulates cell cycle via tumor suppressor p21 expression.

Authors:  Teruki Yanagi; Ko Nagai; Hiroshi Shimizu; Shu-Ichi Matsuzawa
Journal:  Oncotarget       Date:  2017-07-22

8.  Resveratrol acts via melanoma-associated antigen A12 (MAGEA12)/protein kinase B (Akt) signaling to inhibit the proliferation of oral squamous cell carcinoma cells.

Authors:  Yu Shang; Yu-Ling Jiang; Li-Jun Ye; Li-Na Chen; Yue Ke
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.